ALLMedicine™ Meningioma Center

May 18th, 2022 - We present a unique case of biopsy-proven necrotising sarcoidosis involving the central nervous system in a man in his 40s. The patient presented with a 2-week history of right-sided headache and diplopia. He had right trochlear and abducens nerve...

May 17th, 2022 - PRIMARY OBJECTIVES: I. To estimate the efficacy of lutetium Lu 177 dotatate (LUTATHERA) treatment in patients with recurrent grade 1 meningioma as measured by 6-month progression-free survival (PFS) rate. II. To estimate the efficacy of LUTATHERA ...

May 16th, 2022 - NF2 alteration is the most commonly-found genetic abnormality in meningiomas and is known to initiate events for aggressive-type meningiomas. Whereas the prognosis of meningiomas differs depending on their epigenomic/transcriptomic profile, the ef...

May 14th, 2022 - The authors describe a rare case of primary extradural ectopic meningioma of the orbit in a 13-year-old female managed with surgical excision, adding to the very limited literature of this diagnosis in children. This is the second case to show a r...

May 14th, 2022 - Meningioma is the most common primary central nervous system neoplasm, accounting for about a third of all brain tumors. Because their growth rates and prognosis cannot be accurately estimated, biomarkers that enable prediction of their biological...

May 29th, 2020 - Stereotactic radiosurgery (SRS) for benign intracranial meningiomas is an established treatment. To summarize the literature and provide evidence-based practice guidelines on behalf of the International Stereotactic Radiosurgery Society (ISRS). Ar...

May 17th, 2022 - PRIMARY OBJECTIVES: I. To estimate the efficacy of lutetium Lu 177 dotatate (LUTATHERA) treatment in patients with recurrent grade 1 meningioma as measured by 6-month progression-free survival (PFS) rate. II. To estimate the efficacy of LUTATHERA ...

May 11th, 2022 - This is a multi-center, proof of concept phase 0 study to assess the suppression of p-AKT in VS and meningiomas by AR-42 in adult patients undergoing NF2-tumor resection. AR-42 will be administered three times per week beginning 3 weeks prior to s...

Apr 22nd, 2022 - PRIMARY OBJECTIVES: I. To determine progression free survival (PFS) for 6 months (PFS-6) in patients with recurrent or progressive meningioma. SECONDARY OBJECTIVES: I. To determine overall survival (OS). II. To determine tumor response rate (TRR)....

Apr 20th, 2022 - This Phase 3 open-label single-arm study is designed to investigate the safety, diagnostic performance, and clinical usefulness of the imaging agent Gleolan™ (Aminolevulinic Acid Hydrochloride, ALA HCl, ALA, 5-ALA), an orally administered imaging ...

Apr 19th, 2022 - PRIMARY OBJECTIVES: I. To determine the activity of a SMO inhibitor in patients with meningiomas harboring SMO and PTCH1 mutations as measured by 6-month progression free survival (PFS) and response rate. II. To determine the activity of a FAK inh...

Feb 15th, 2022 - New research shows that men in their 20s and 30s have worse survival from many different types of brain tumors than women of the same age. And, researchers say, it’s not exactly clear why. Differences in treatment may mediate some of the associati...

Oct 6th, 2021 - By 2030, it is projected that most Americans will be overweight, and of those, nearly 50% of adults will be obese. Although the majority of Americans are aware that obesity can have adverse health consequences, survey findings show that few are aw...

Feb 3rd, 2021 - New details confirm an increased risk of developing intracranial meningiomas after prolonged use of the hormonal product cyproterone acetate. Cyproterone acetate is a synthetic progestogen and potent anti-androgen that has been used in the treatme...

Dec 5th, 2020 - Elizabeth B. Claus, MD New data suggest that dental x-rays obtained frequently at a young age may boost the risk of intracranial meningioma. Although dental x-rays are an important tool in well selected patients, efforts to moderate exposure to ...

Dec 5th, 2020 - Alexander Drilon, MD Research on the proto-oncogene RET has accelerated exponentially since 1985, when Masahide Takahashi, MD, PhD, and colleagues first reported a fusion rearrangement in lymphoma DNA.1 Early progress was slow. Other investigator...